Page 176 - Read Online

Page 145 Hjalgrim et al. J Transl Genet Genom 2022;6:134-46 https://dx.doi.org/10.20517/jtgg.2021.46

48. Diepstra A, van Imhoff GW, Schaapveld M, et al. Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin’s lymphoma
predicts adverse outcome in older adult patients. J Clin Oncol 2009;27:3815-21. DOI PubMed
49. Küppers R, Rajewsky K, Zhao M, et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show
clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad
Sci U S A 1994;91:10962-6. DOI PubMed PMC
50. Kanzler H, Küppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin’s disease represent the outgrowth
of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 1996;184:1495-505. DOI PubMed PMC
51. Marafioti T, Hummel M, Foss HD, et al. Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a
germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood
2000;95:1443-50. PubMed
52. Mancao C, Altmann M, Jungnickel B, Hammerschmidt W. Rescue of “crippled” germinal center B cells from apoptosis by Epstein-
Barr virus. Blood 2005;106:4339-44. DOI PubMed PMC
53. Jarrett RF, Hjalgrim H, Murray PG. The role of viruses in the genesis of Hodgkin lymphoma. In: Engert A, Younes A, editors.
Hodgkin lymphoma - a comprehensive review. Cham: Springer; 2018. p. 25-46. DOI
54. Rosenwald A, Küppers R. Pathology and molecular pathology of Hodgkin lymphoma. In: Engert A, Younes A, editors. Hodgkin
lymphoma - a comprehensive overview, Cham: Springer; 2020. p. 47-68. DOI
55. Murray PG, Young LS. An etiological role for the Epstein-Barr virus in the pathogenesis of classical Hodgkin lymphoma. Blood
2019;134:591-6. DOI PubMed
56. Murray P, Ibrahim M. Role of EBV in classical Hodgkin lymphoma. In: Hudnall SD, Küppers R, editors. Precision molecular
pathology of Hodgkin lymphoma. Cham: Springer; 2018. p. 91-110. DOI
57. Ambinder RF. Gammaherpesviruses and “Hit-and-Run” oncogenesis. Am J Pathol 2000;156:1-3. DOI PubMed PMC
58. Visser L, Veldman J, Poppema S, van den Berg A, Diepstra A. Microenvironment, cross-talk, and immune escape mechanisms. In:
Engert A, Younes A, editors. Hodgkin lymphoma - a comprehensive overview. Cham: Springer; 2020. p. 69-86. DOI
59. Chetaille B, Bertucci F, Finetti P, et al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor
microenvironment and correlations with EBV infection and outcome. Blood 2009;113:2765-3775. DOI PubMed
60. Ghosh SK, Perrine SP, Williams RM, Faller DV. Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV
and sensitize lymphoma cells to nucleoside antiviral agents. Blood 2012;119:1008-17. DOI PubMed PMC
61. Porcu P, Haverkos B, Alpdogan O, et al. Oral nanatinostat (Nstat) and valganciclovir (VGCV) in patients with recurrent Epstein-Barr
virus (EBV)-positive lymphomas: initial phase 2 results. Blood 2020;136:7-8. DOI
62. Perrine SP, Hermine O, Small T, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-
associated lymphoid malignancies. Blood 2007;109:2571-8. DOI PubMed PMC
63. Nijland M, Veenstra RN, Visser L, et al. HLA dependent immune escape mechanisms in B-cell lymphomas: implications for immune
checkpoint inhibitor therapy? Oncoimmunology 2017;6:e1295202. DOI PubMed PMC
64. Bollard CM, Gottschalk S, Torrano V, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T
lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol 2014;32:798-808. DOI PubMed PMC
65. Ho C, Ruella M, Levine BL, Svoboda J. Adoptive T-cell therapy for Hodgkin lymphoma. Blood Adv 2021;5:4291-302. DOI PubMed
66. Bollard CM, Tripic T, Cruz CR, et al. Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses
in patients with relapsed hodgkin lymphoma. J Clin Oncol 2018;36:1128-39. DOI PubMed PMC
67. Heslop HE, Sharma S, Rooney CM. Adoptive T-cell therapy for Epstein-Barr virus-related lymphomas. J Clin Oncol 2021;39:514-24.
DOI PubMed PMC
68. Rouce RH, Mehta B, Sharma S, et al. Rapidly-generated EBV-specific T cells (EBVST-cells) to treat type 2 latency lymphoma. Blood
2016;128:2990. DOI
69. Curran KJ, Sauter CS, Kernan NA, et al. Durable remission following “off-the-shelf” chimeric antigen receptor (CAR) T-cells in
patients with relapse/refractory (R/R) B-cell malignancies. Biol Blood Marrow Tr 2020;26:S89. DOI
70. Dalton T, Doubrovina E, Pankov D, et al. Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-
directed immunotherapy. Blood 2020;135:1870-81. DOI PubMed PMC
71. Choi IK, Wang Z, Ke Q, et al. Mechanism of EBV inducing anti-tumour immunity and its therapeutic use. Nature 2021;590:157-62.
DOI PubMed PMC
72. Mottok A, Steidl C. Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies. Blood 2018;131:1654-
65. DOI PubMed
73. Kamper P, Bendix K, Hamilton-Dutoit S, Honoré B, Nyengaard JR, d’Amore F. Tumor-infiltrating macrophages correlate with
adverse prognosis and Epstein-Barr virus status in classical Hodgkin’s lymphoma. Haematologica 2011;96:269-76. DOI PubMed
PMC
74. Guo B, Cen H, Tan X, Ke Q. Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical
Hodgkin lymphoma. BMC Med 2016;14:159. DOI PubMed PMC
75. Vari F, Arpon D, Keane C, et al. Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in
Hodgkin lymphoma than DLBCL. Blood 2018;131:1809-19. DOI PubMed PMC
76. Advani RH, Moskowitz AJ, Bartlett NL, et al. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin
lymphoma: 3-year study results. Blood 2021;138:427-38. DOI PubMed
77. Reinke S, Bröckelmann PJ, Iaccarino I, et al. Tumor and microenvironment response but no cytotoxic T-cell activation in classic
Hodgkin lymphoma treated with anti-PD1. Blood 2020;136:2851-63. DOI PubMed